Research Status of Carrier-free Nano Antitumor Drugs: The Mechanism of Action and Future Trends of Four Carrier-free Nanomedicines

Dongjun Zuo

2022

Abstract

At present, there are four mainstream carrier-free nano anti-tumor drugs. The prodrug self-delivery system uses self-assembled targeted drugs constructed with small groups and anti-cancer drugs. A pure drug delivery system that uses two or more pure drugs to construct self-assembled drug-drug conjugates. Based on the self-delivery system of therapeutic carriers, a self-assembled anticancer drug is constructed using carriers with auxiliary therapeutic effects. Based on the self-delivery system of non-toxic agents, non-toxic groups are used to assist anticancer drugs to function. Carrier-free nano anticancer drugs solve the side effects of traditional nano anticancer drugs that nanocarriers cannot be metabolized by the body, and have broad research prospects.

Paper Citation

in Harvard Style

Zuo D. (2022). Research Status of Carrier-free Nano Antitumor Drugs: The Mechanism of Action and Future Trends of Four Carrier-free Nanomedicines. In Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB, ISBN 978-989-758-595-1, pages 434-439. DOI: 10.5220/0011214100003443

in Bibtex Style

@conference{icbeb22,
author={Dongjun Zuo},
title={Research Status of Carrier-free Nano Antitumor Drugs: The Mechanism of Action and Future Trends of Four Carrier-free Nanomedicines},
booktitle={Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,},
year={2022},
pages={434-439},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0011214100003443},
isbn={978-989-758-595-1},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 4th International Conference on Biomedical Engineering and Bioinformatics - Volume 1: ICBEB,
TI - Research Status of Carrier-free Nano Antitumor Drugs: The Mechanism of Action and Future Trends of Four Carrier-free Nanomedicines
SN - 978-989-758-595-1
AU - Zuo D.
PY - 2022
SP - 434
EP - 439
DO - 10.5220/0011214100003443